StocktoriaSenti Biosciences Holdings, Inc. SNTI
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
2/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $22,000 | $0 | $2.6M | $4.3M | $2.8M |
| Operating income | -$68.8M | -$61.0M | -$92.7M | -$62.1M | -$40.4M |
| Net income | -$61.4M | -$52.8M | -$71.1M | -$58.2M | -$55.3M |
| Operating cash flow | -$43.4M | -$41.4M | -$52.4M | -$34.9M | -$34.6M |
| Free cash flow | -$43.6M | -$41.4M | -$64.4M | -$76.3M | -$40.2M |
| Total assets | $51.2M | $97.8M | $119.5M | $180.8M | $96.7M |
| Total liabilities | $45.6M | $47.1M | $52.6M | $53.5M | $36.3M |
| Shareholders' equity | $5.6M | $25.6M | $66.9M | $127.3M | -$111.5M |
| Ratios | |||||
| Operating margin | -312631.8% | — | -3620.7% | -1448.5% | -1464.9% |
| Net margin | -279263.6% | — | -2774.6% | -1358.1% | -2003.6% |
| FCF margin | -198363.6% | — | -2515.9% | -1779.5% | -1455.2% |
| Return on assets | -119.9% | -54.0% | -59.5% | -32.2% | -57.2% |
| Return on equity | -1099.3% | -205.8% | -106.2% | -45.7% | 49.6% |
| Current ratio | 1.67 | 4.49 | 5.62 | 5.68 | 4.14 |
| Revenue growth | — | -100.0% | -40.2% | 55.2% | — |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001854270 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.